Jeanette Lundin

3.3k total citations
53 papers, 2.2k citations indexed

About

Jeanette Lundin is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Jeanette Lundin has authored 53 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Genetics, 33 papers in Immunology and 31 papers in Pathology and Forensic Medicine. Recurrent topics in Jeanette Lundin's work include Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (31 papers) and Immunodeficiency and Autoimmune Disorders (25 papers). Jeanette Lundin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (31 papers) and Immunodeficiency and Autoimmune Disorders (25 papers). Jeanette Lundin collaborates with scholars based in Sweden, Denmark and United States. Jeanette Lundin's co-authors include Anders Österborg, Håkan Mellstedt, Eva Kimby, Claes Karlsson, Hans Hagberg, Roland Repp, Anders Österborg, Fredrik Celsing, Herman Waldmann and G Hale and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jeanette Lundin

51 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeanette Lundin Sweden	21	1.1k	1.1k	1.1k	544	448	53	2.2k
Anne Tierens Norway	29	914 0.8×	659 0.6×	572 0.5×	778 1.4×	590 1.3×	101	2.2k
Bernard Lenormand France	20	949 0.8×	638 0.6×	336 0.3×	512 0.9×	355 0.8×	52	1.6k
G. Tertian France	17	522 0.5×	684 0.6×	527 0.5×	364 0.7×	578 1.3×	48	2.0k
Marina P. Siakantaris Greece	22	766 0.7×	525 0.5×	273 0.3×	430 0.8×	265 0.6×	74	1.4k
Monica Bocchia Italy	28	850 0.7×	1.1k 1.0×	964 0.9×	1.0k 1.9×	1.3k 2.9×	179	2.9k
Marco Fizzotti Italy	17	1.4k 1.2×	479 0.4×	459 0.4×	876 1.6×	243 0.5×	38	2.0k
Masataka Okamoto Japan	27	1.8k 1.6×	738 0.7×	358 0.3×	1.1k 2.0×	176 0.4×	77	2.5k
Charles Herbaux France	23	1.2k 1.0×	1.1k 1.0×	591 0.6×	675 1.2×	460 1.0×	111	1.9k
WC Chan United States	19	959 0.8×	405 0.4×	707 0.7×	718 1.3×	149 0.3×	26	1.6k
P. M. Kluin Netherlands	21	1.0k 0.9×	431 0.4×	314 0.3×	797 1.5×	260 0.6×	40	1.8k

Countries citing papers authored by Jeanette Lundin

Since Specialization

Citations

This map shows the geographic impact of Jeanette Lundin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeanette Lundin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeanette Lundin more than expected).

Fields of papers citing papers by Jeanette Lundin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeanette Lundin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeanette Lundin. The network helps show where Jeanette Lundin may publish in the future.

Co-authorship network of co-authors of Jeanette Lundin

This figure shows the co-authorship network connecting the top 25 collaborators of Jeanette Lundin. A scholar is included among the top collaborators of Jeanette Lundin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeanette Lundin. Jeanette Lundin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kokhaei, Parviz, Ali Moshfegh, Jeanette Lundin, et al.. (2024). A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL). Cancers. 16(22). 3821–3821. 3 indexed citations

Hojjat‐Farsangi, Mohammad, Ann Svensson, Jeanette Lundin, et al.. (2023). A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (KAND567) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells. Blood. 142(Supplement 1). 5716–5716. 1 indexed citations

Lundin, Jeanette, Tove Wästerlid, Håkan Mellstedt, et al.. (2021). Temporary cessation of ibrutinib results in reduced grade 3‐4 infections and durable remissions—Interim analysis of an on‐off‐repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia. SHILAP Revista de lepidopterología. 2(3). 525–529. 1 indexed citations

Lundin, Jeanette, Larry Mansouri, Richard Rosenquist, et al.. (2020). Risk‐adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real‐world report on 141 consecutive Swedish patients. British Journal of Haematology. 191(3). 426–432. 5 indexed citations

Stasiłojć, Grzegorz, Anna Felberg, A Urban, et al.. (2019). Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies. Journal of Immunological Methods. 476. 112675–112675. 5 indexed citations

Andersson, Per‐Ola, Karin Karlsson, Claes Karlsson, et al.. (2017). Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program. Blood. 130. 5353. 2 indexed citations

Mozaffari, Fariba, Marzia Palma, Lotta Hansson, et al.. (2016). Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints. Cancer Immunology Immunotherapy. 66(1). 91–102. 8 indexed citations

Mozaffari, Fariba, et al.. (2015). In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study. Blood. 126(23). 4164–4164. 2 indexed citations

Hansson, Lotta, et al.. (2013). Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region. Leukemia & lymphoma. 55(8). 1774–1780. 8 indexed citations

10.

Norin, Stefan, Eva Kimby, & Jeanette Lundin. (2009). Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia. Medical Oncology. 27(3). 820–825. 10 indexed citations

11.

Gunnarsson, Rebeqa, Anders Isaksson, Mahmoud Mansouri, et al.. (2009). Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: A high-resolution genomic screening in newly diagnosed patients. Lund University Publications (Lund University). 94. 354–354. 1 indexed citations

12.

Österborg, Anders, Claes Karlsson, & Jeanette Lundin. (2008). Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports. 4(1). 47–53. 21 indexed citations

13.

Näsman, Per, Lucia Ahlberg, Torbjörn Karlsson, et al.. (2007). Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 21(4). 627–632. 159 indexed citations

14.

Österborg, Anders, Claes Karlsson, Jeanette Lundin, Eva Kimby, & Håkan Mellstedt. (2006). Strategies in the Management of Alemtuzumab-Related Side Effects. Seminars in Oncology. 33(2 Suppl 5). 29–35. 43 indexed citations

15.

Kiaii, Shahryar, Aniruddha Choudhury, Fariba Mozaffari, et al.. (2006). Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment. Leukemia & lymphoma. 47(7). 1229–1238. 10 indexed citations

16.

Kokhaei, Parviz, A Choudhury, Reza Mahdian, et al.. (2004). Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia. 18(11). 1810–1815. 60 indexed citations

17.

Lundin, Jeanette, Eva Kimby, Magnus Björkholm, et al.. (2001). Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).. Blood. 98. 4 indexed citations

18.

Rossmann, Eva, Jeanette Lundin, Rodiça Lenkei, Håkan Mellstedt, & Anders Österborg. (2001). Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. The Hematology Journal. 2(5). 300–306. 60 indexed citations

19.

Hassan, Moustapha, et al.. (1999). The influence of interferon‐α on the pharmacokinetics of cyclophosphamide and its 4‐hydroxy metabolite in patients with multiple myeloma. European Journal Of Haematology. 63(3). 163–170. 17 indexed citations

20.

Österborg, Anders, Eva Halapi, Jeanette Lundin, et al.. (1997). Clonal CD8₊ and CD52_– T cells are induced in responding B cell lymphoma patients treated with Campath‐1H* (anti‐CD52). European Journal Of Haematology. 58(1). 5–13. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact